Research programme: sodium channel blockers - RaQualia Pharma

Drug Profile

Research programme: sodium channel blockers - RaQualia Pharma

Alternative Names: RQ-00203066

Latest Information Update: 27 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma
  • Class Amides
  • Mechanism of Action Nav1.3 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammatory pain; Neuropathic pain

Most Recent Events

  • 27 Jul 2016 Early research and development is ongoing in Japan
  • 25 Jul 2016 Raqualia receives patent allowance for Sodium channel blockers in China
  • 25 Jul 2016 RaQualia has patent protection for Sodium channel blockers in Japan, USA, South Korea, Europe and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top